Search Results
Your search for them matches 6128 pages
Showing 3251 - 3300EXPERT POINT OF VIEW: Robert Brodsky, MD
“THE RESULTS of these two trials are more similar than different. I think the best conclusion would be that we now have two trials with consistent results and can probably, in most cases, replace low–molecular-weight heparin with direct oral anticoagulants,” said Dr. Raskob, lead investigator of...
Use of Direct Oral Anticoagulants in Preventing VTE in Patients With Cancer
THE FIRST TWO randomized trials to directly compare direct oral anticoagulants vs low–molecular-weight heparin for management of venous thromboembolism (VTE) in patients with cancer suggest that direct oral anticoagulants may become the new standard of care.1,2 Direct oral anticoagulants appear to...
EXPERT POINT OF VIEW: Ann H. Partridge, MD, MPH, FASCO
“The simple questions are whether ovarian function suppression adds clinical benefit in premenopausal women, and is ovarian function suppression better with an aromatase inhibitor or tamoxifen,” said formal discussant of these trials, Ann H. Partridge, MD, MPH, FASCO, Professor of Medicine at...
SABCS Highlights Focus on Predicting Residual Tumor Burden, Therapy-Related Arm Morbidity, Lifestyle and Cancer Risk
We have covered many of the important presentations from the 2017 San Antonio Breast Cancer Symposium in the pages of The ASCO Post and in our online Evening News. Here are summaries of additional noteworthy studies presented at the meeting. We hope you will find them of interest. Predicting...
Combined Medical and Psychological Approach May Help Couples Reclaim Intimacy After Prostate Cancer Treatment
“To what extent do treatments for prostate cancer impact sexual functioning? To a great extent,” Christian Nelson, PhD, Chief, Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, told participants at the 11th Annual Oncofertility Consortium Conference in Chicago.1 Most men with...
LAPACT Trial Confirms Efficacy of Nab-Paclitaxel Plus Gemcitabine as Induction Therapy in Pancreatic Cancer
Patients newly diagnosed with locally advanced pancreatic cancer who received induction therapy with nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) and gemcitabine achieved a time to treatment failure and median progression-free survival that exceeded the protocol-specified target by more...
Use of Circulating Tumor Cells to Detect Colorectal Cancer and Adenomas
Circulating tumor cells (CTCs) in the blood had an accuracy of up to 88% in detecting colorectal cancer and 84% in identifying adenomas, in a study from Taiwan presented at the 2018 Gastrointestinal Cancers Symposium by Wen-Sy Tsai, MD, of Linkou Chang Gung Memorial Hospital in Taipei.1 “The study ...
EXPERT POINT OF VIEW: Jordi Bruix, MD, PhD and Flavio G. Rocha, MD
Discussant Jordi Bruix, MD, PhD, Head of the Barcelona Clinic Liver Cancer Group at the University of Barcelona in Spain, said the results of the CELESTIAL trial show that cabozantinib (Cabometyx) provides a clinically meaningful survival benefit to patients with advanced hepatocellular carcinoma ...
Releasing Follicular Lymphoma From the Curse of Frankenstein
In the December 10, 2017, issue of The ASCO Post, I authored an article in which I raised the possibility of curing follicular lymphoma without the dreaded chemotherapy. Clearly, no good deed goes unpunished: My good friend and The ASCO Post’s editor Jim Armitage, MD, challenged me to defend that...
2018 SURVIVORSHIP: Therapeutic Sexual Aids Frequently Not Available for Cancer Survivors Who Need Them
Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site...
Synchronous Distant and Locoregional Recurrence in Stage II and III Breast Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Neuman et al found that synchronous distant recurrence was identified in 27% of women with stage II or III breast cancer experiencing locoregional recurrence. Study Details The study—an American...
CancerLinQ LLC Partners With the National Society of Genetic Counselors
CancerLinQ LLC and the National Society of Genetic Counselors (NSGC), the professional society for genetic counselors, announced that they have entered into a strategic alliance. With the collaboration, NSGC leaders and members will provide expertise to CancerLinQ®, ASCO’s health information...
Highlights From the 2018 Gastrointestinal and Genitourinary Cancers Symposia
THE 2018 GASTROINTESTINAL CANCERS SYMPOSIUM was held January 18–20, and the 2018 Genitourinary Cancers Symposium was held February 8–10. Help keep your patients informed by directing them to www.Cancer.Net/blog to read about the most exciting research presented at these conferences. ■ © 2018....
Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.1 “At this time point, our study showed no difference in disease-free survival or overall survival between 5 years ...
Precision Medicine: Hope or Hype?
ALTHOUGH PRECISION medicine may be a recent discovery in some fields, it is an old story in the field of breast cancer, and one that has been exceptionally important in terms of managing the disease, according to George Sledge, MD, FASCO, Professor of Medicine and Medical Oncologist at the...
Amyloid-Targeting Antibody Elicits Organ Responses in Patients With Amyloidosis
IN PREVIOUSLY treated patients with amyloid light-chain (AL) amyloidosis, the chimeric fibril-reactive monoclonal antibody 11-1F4 (CAEL-101) produced organ responses in about two-thirds of patients in a phase Ia/b trial reported at the 2017 American Society of Hematology (ASH) Annual Meeting &...
Patient Refusal of Esophagectomy and Long-Term Survival
Patients with esophageal cancer who refuse surgery when it is recommended are less likely to survive long term than similar groups of patients who undergo an operation, according to research presented by Ghaly et al at the 54th Annual Meeting of The Society of Thoracic Surgeons (P78). ...
Scientific Statement From the American Heart Association Examines Intersection of Breast Cancer and Cardiovascular Disease
Patients with breast cancer may be at an increased risk of cardiovascular diseases, including heart failure, and may benefit from a treatment approach that weighs the benefits of specific therapies against potential damage to the heart, according to a new scientific statement from the American...
Bone-Modifying Agents in Metastatic Breast Cancer: Time to De-escalate Dosing Intervals
AS REVIEWED in this issue of The ASCO Post, ASCO and Cancer Care Ontario (CCO) have issued an updated guideline on the role of bone-modifying agents in metastatic breast cancer.1 The updated guideline supports a change in clinical practice for our patients with breast cancer and bone metastasis....
Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer
The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends documented “are remarkable for their steepness of decline, independent of clinical factors and despite no...
Up-to-Date Labels for Older Drugs Essential for Appropriate Use
Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may be missing. Modernizing the labeling process can correct inaccurate information, add data for indications ...
The Roller Coaster
The following essay by Shaker R. Dakhil, MD, FACP, is adapted, with permission, from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and...
Making Personalized Medicine a Reality for More Patients With Cancer
This past September, Olivier Elemento, PhD, Associate Director of the Institute for Computational Biomedicine and Director of the Laboratory of Cancer Systems Biology at Weill Cornell Medicine in New York, was named Director of Weill Cornell’s Englander Institute for Precision Medicine. In this...
For Holly G. Prigerson, PhD, Psychosocial Issues Are at the Heart of End-of-Life Cancer Care
Holly G. Prigerson, PhD, Co-Director of the Weill Cornell Medicine’s Center for Research on End-of-Life Care, was born in Maimonides Hospital in Brooklyn, where her father had been a resident. Her family moved to Long Island, first living in Islip, where Dr. Prigerson’s father practiced medicine...
Fox Chase Announces Winners of ACS Institutional Research Grant for Junior Investigators
Fox Chase Cancer Center and the Lewis Katz School of Medicine are pleased to announce the winners of its American Cancer Society (ACS) Institutional Research Grant Pilot Project Competition for Junior Investigators. The competition was open to eligible junior faculty at Fox Chase Cancer Center and ...
Plasma Epstein-Barr Virus DNA Screening for Nasopharyngeal Cancer
In a Hong Kong study reported in The New England Journal of Medicine, K.C. Allen Chan, MBBS, PhD, MRCP, FRCPA, FHKCPath, FHMAM, of The Chinese University of Hong Kong, Department of Chemical Pathology, and colleagues found that screening for circulating cell-free Epstein-Barr virus (EBV) DNA is...
The Telltale Heart: A Surgeon’s Memoir
We don’t feel our liver or pancreas working, but we all feel our hearts beating—the drumbeat of our mortality since we all have a finite number of heartbeats from birth to death. And unlike with most other organs, we are painfully aware of how fragile this mighty muscle can be. About 610,000 people ...
Internationally Renowned Prostate Cancer Expert Gerald E. Hanks, MD, Dies
FROM WILHELM RÖNTGEN’S groundbreaking discovery of x-rays in 1895, the history of radiotherapy has been rich with colorful paradigm-changing researchers and physicians who over the past century have transformed the field into one of the pillars of cancer treatment. One such trailblazer who...
A Neuroscientist Examines Intact Minds Adrift in Damaged Brains and Bodies
Understanding what consciousness is, and why and how it evolved, is perhaps the greatest mystery known to science. With its 100 billion or so neurons and a processing rate of about 4 billion bits per second, the human brain is a miraculously complicated entity, much of which is still under...
Against All Odds
The days leading up to our daughter Emily’s diagnosis of acute lymphoblastic leukemia (ALL) on May 28, 2010, when she was just 5, offered few clues about the terrifying, life-and-death months and years we were about to experience. She was happy and seemingly healthy, literally until the day before...
Working Together to Help Pediatric Patients With Cancer Live and Live Well
While many patients with cancer can benefit from palliative care to ease symptoms from the disease or its treatment, for children with cancer, especially critically ill children, palliative care can provide an additional layer of medical and emotional support for both young patients and their...
ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLC
As reported in the Journal of Clinical Oncology by Bryan J. Schneider, MD, of the University of Michigan, Ann Arbor, and colleagues, ASCO has endorsed the recently released American Society for Radiation Oncology (ASTRO) evidence-based guideline on stereotactic body radiotherapy (SBRT) in early...
Diary of a Storm
FOR DAYS BEFORE HURRICANE HARVEY was expected to move toward Houston, Texas, on Sunday, August 27, 2017, after pummeling other cities in Texas and Louisiana, the leadership team at The University of Texas MD Anderson Cancer Center (MD Anderson) in Houston strategized on how to ensure the...
Mackenzi Pergolotti, PhD, OTR/L: A Leader in the Emerging Field of Occupational Therapy in Oncology
Oncology occupational therapist Mackenzi Pergolotti, PhD, OTR/L, was born in Buffalo, New York. “I lived there until I was 6,” she shared. “Then my family moved around the state a bit, finally settling in the small town of Bath, situated near the Finger Lakes—a beautiful area in central New ...
Listen to Conquer Cancer Mini-Podcasts Inspired by StoryCorps and ASCO Members, Grantees
Debuting this year, “Your Stories: Conquering Cancer” are unscripted conversations among doctors, patients, and caregivers who have been affected by cancer. The Conquer Cancer Foundation produced the mini-podcast series through the award-winning StoryCorps organization, a national nonprofit...
Now Available: Limited Edition Conquer Cancer Foundation Nike Sneakers
PURCHASE A pair of limited edition ASCO’s Conquer Cancer Foundation Nike Roshe LD-1000 sneakers, available exclusively from Conquer Cancer. The sneakers celebrate 15.5 million cancer survivors across the United States and are a great way to start the new year on the right foot! Sizes are limited;...
Preserving Sexual Function in Women Treated for Cancer
“There is huge potential to positively influence a patient’s experience and outcomes” by addressing concerns about sexual function after cancer treatment early in the course of treatment planning, Stacy Tessler Lindau, MD, MA, stated in her keynote address at the 11th Annual Oncofertility...
Study Describes Structure of Tumor Herpes Virus Associated With Kaposi's Sarcoma
Researchers from the University of California, Los Angeles (UCLA) have provided the first description of the structure of the herpes virus associated with Kaposi’s sarcoma. The findings, published by Dai et al in Nature, answer important questions about how the virus spreads and provide a...
Circulating Tumor Cells May Predict Late Recurrence in Hormone Receptor–Positive Breast Cancer
In patients with early breast cancer, the presence in the blood of circulating tumor cells 5 years after diagnosis increases the risk for recurrence nearly 20-fold, researchers reported at the 2017 San Antonio Breast Cancer Symposium.1 “We found that a single positive circulating tumor cell assay...
Power of Pathologic Complete Response to Neoadjuvant Therapy Demonstrated in I-SPY 2 Trial
More evidence of the power of pathologic complete response (pCR) now comes from an update of the multicenter, adaptively randomized I-SPY 2 trial. In a study reported at the 2017 San Antonio Breast Cancer Symposium, pCR predicted for event-free and distant disease–free survival in high-risk...
Proof-of-Principle Study of Combination Checkpoint Inhibitor Plus Trastuzumab in HER2-Positive Advanced Breast Cancer
The combination of pembrolizumab (Keytruda) plus trastuzumab (Herceptin) may turn out to be a good treatment option for patients with trastuzumab-resistant advanced HER2-positive breast cancer, according to the results of an early study presented at the 2017 San Antonio Breast Cancer Symposium...
Expert Point of View: Virginia Kaklamani, MD and Harold Burstein, MD, PhD, FASCO
Press briefing moderator Virginia Kaklamani, MD, Professor of Medicine at The University of Texas Health Science Center, San Antonio, along with Harold Burstein, MD, PhD, FASCO, Associate Professor of Medicine at Harvard Medical School, commented on the National Surgical Adjuvant Breast and Bowel ...
NSABP B-47: No Benefit for Adjuvant Trastuzumab in HER2-Low Breast Cancer
For more than a decade, breast cancer experts have wondered whether women with low levels of HER2 might derive some benefit from trastuzumab (Herceptin), based on signals seen in earlier trastuzumab trials. Most notably, in the landmark National Surgical Adjuvant Breast and Bowel Project (NSABP) ...
Celebrating the Life of Jimmie Holland, MD
The oncology community mourns the sudden passing of Jimmie C. Holland, MD, who died on December 24, 2017, at the age of 89. Dr. Holland’s achievements over her 40-year career are legend. They include the founding of the subspecialty of psycho-oncology, the establishment of a full-time Psychiatry...
Novel Antibody-Drug Conjugate Active in Refractory Triple-Negative Breast Cancer
In relapsed or refractory triple-negative breast cancer, the antibody-drug conjugate sacituzumab govitecan (IMMU-132) demonstrated significant clinical activity in an open-label study presented at the 2017 San Antonio Breast Cancer Symposium.1 “Metastatic triple-negative breast cancer is an...
ACCC 2017 Survey Shows Cost of Treatment Is Top Threat to Cancer Program Growth
The Association of Community Cancer Centers (ACCC) 8th annual Trending Now in Cancer Care survey, conducted in partnership with Advisory Board’s Oncology Roundtable, has identified current and emerging trends across U.S. cancer programs. When asked to identify the top threats to future cancer ...
Study Finds Desmoplastic Melanoma Highly Responsive to PD-1/PD-L1 Blockade
Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients. Treatment is difficult, as these tumors are often resistant to chemotherapy and lack actionable mutations commonly found in other types of...
Study Finds Gene-Expression Profile Testing for Breast Cancer Less Cost-Effective in Real-World Practice
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by scientists from Georgetown Lombardi Comprehensive Cancer Center. Their study, published by Chandler et al in the Journal...
Is Medical Assistance in Dying Compassionate Care?
Suicidal ideation while receiving end-of-life cancer care is not unusual but can often be reversed by palliative and psychosocial oncology interventions. That said, there are patients who, even after intensive interventions, request medical assistance in dying. Physician-assisted death has been a...
Helping Patients With Head and Neck Cancer and Their Caregivers Face Treatment-Associated Challenges
Head and neck cancer remains one of the most challenging clinical presentations faced by the oncology community. Patients must not only face a potentially lethal disease, but must also cope with treatments that often result in significant side effects. To gain a better understanding on the...
